Here's how the ASX 200 market sectors stacked up last week

Healthcare was the strongest sector last week, with market darling Pro Medicus surging yet again.

Medical or healthcare workers grasp hands in the universal expression of teamwork

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX 200 healthcare shares led the market sectors with a 1.15% increase over the five trading days.

The S&P/ASX 200 Index (ASX: XJO) gained 0.53% over the week to finish at 8,294.1 points on Friday.

Seven of the 11 market sectors finished the week in the green.

Let's review the week's events.

Healthcare shares led the ASX sectors last week

Among the healthcare sector heavyweights, CSL Ltd (ASX: CSL) shares lifted 0.59% to $285.09.

Pro Medicus Ltd (ASX: PME) shares rose 5.92% despite no price-sensitive news last week.

Pro Medicus continues to ride a positive wave of momentum after delivering the best share price growth among the ASX 200 large-cap shares last year.

Resmed CDI (ASX: RMD) shares lifted 2.72% to $37.76 per share. Resmed announced it will reveal its second-quarter results on 30 January.

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares lifted 0.35% to $34.30 apiece.

The Cochlear Ltd (ASX: COH) share price rose 0.92% to $301.20.

Shares in pathology provider Sonic Healthcare Ltd (ASX: SHL) lifted 1.56% to close at $27.99 on Friday.

Telix Pharmaceuticals Ltd (ASX: TLX) shares ascended 0.63% to $23.99.

Other strong performers last week include Sigma Healthcare Ltd (ASX: SIG) shares, which gained 7.91% and hit an almost two-decade high of $3.05 on Friday. The Sigma share price closed the week at $3.

Last week, the Amcal chemist owner did not provide any news, as excited investors awaited the conclusion of its merger with Chemist Warehouse.

Among the fallers last week were Clarity Pharmaceuticals Ltd (ASX: CU6) shares, which lost 5.61% in value to close at $3.87 on Friday.

Mesoblast Ltd (ASX: MSB) shares lost 11.36% between Monday and Thursday before going into a trading halt prior to Friday's market open.

The company intends to make an announcement about a "proposed financing" shortly.

For now, the Mesoblast share price is frozen at $2.81. The ASX biotech asked for the trading halt to remain in place until the time of the announcement or the commencement of trading on Tuesday.

Mesoblast shares are still up a whopping 65% despite last week's share price correction.

Investors have been buying Mesoblast shares after the company finally gained approval from the United States Food and Drug Administration for its lead drug, remestemcel-L, last month.

Stock in private healthcare provider and hospital owner Ramsay Health Care Ltd (ASX: RHC) also fell last week. The Ramsay share price lost 2.48% to finish the week at $33.75 per share.

ASX 200 market sector snapshot

Here's how the 11 market sectors stacked up last week, according to CommSec data.

Over the five trading days:

S&P/ASX 200 market sectorChange last week
Healthcare (ASX: XHJ) 1.15%
Financials (ASX: XFJ)0.83%
Information Technology (ASX: XIJ)0.76%
Consumer Discretionary (ASX: XDJ)0.74%
Materials (ASX: XMJ)0.71%
A-REIT (ASX: XPJ)0.42%
Utilities (ASX: XUJ)0.02%
Communication (ASX: XTJ)(0.21%)
Industrials (ASX: XNJ) (0.31%)
Energy (ASX: XEJ)(0.49%)
Consumer Staples (ASX: XSJ) (1.56%)

Motley Fool contributor Bronwyn Allen has positions in CSL and Mesoblast. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Cochlear, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended CSL, Cochlear, Pro Medicus, Sonic Healthcare, and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »

Two brokers analysing stocks.
Healthcare Shares

Why does Macquarie think Fisher & Paykel shares are a buy?

Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) shares have been on form over the past 12 months. During this…

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Which small cap ASX share is jumping 10% on strong results

Investors have been bidding this stock higher today. But why?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why Macquarie forecasts 30-50% upside for these ASX All Ords healthcare stocks

Macquarie updated its target price on these three ASX All Ords healthcare stocks.

Read more »